Normal Amsler Grid appearance.
Appearance of Amsler grid with macular disease.
Note distorted image.
Appearance of Amsler grid with wet AMD.
Note distortion and darkened spot.
Age-related macular degeneration (AMD) is the most common cause of vision loss in persons over 50 years of age world-wide. Millions are affected, and because it is an aging change, AMD is becoming increasingly common as the world population ages.
“Dry” AMD is the earliest stage, and affects everyone with AMD. Most people with dry AMD have good vision on the eye chart, but have increasing difficulty at night and indoors, needing more light and higher contrast (black and white rather than shades of grey) to see well. Severe visual loss with dry AMD is uncommon, and usually occurs when a condition called “geographic atrophy” develops.
“The other day I realized that I was reading the scores at the bottom of the TV screen again. I couldn’t do that before the laser treatment. And the distortion and waviness was gone.” 76 year old woman with dry AMD.
“Wet” AMD is the most common reason people with dry AMD lose vision. This happens when an eye with dry AMD develops scar tissue growth under the center of the retina (called the macula), causing damage that destroys the macula and central, sharp vision. Without macular vision, your ability to read, recognize faces, and drive may be lost.
Retinal Protective Therapy™ (RPT™)
Effective preventive treatment for AMD
Retinal Protective Therapy™ (RPT™) can reduce your risk of developing “wet” AMD. The Age-Related Eye Disease Study (AREDS) showed that vitamins can reduce the risk of visual loss in dry AMD by about 4% per year. Recent studies suggest that RPT can reduce your risk of visual loss by more than 90% per year compared to AREDS vitamins alone. At the same time, RPT™ improves indoor vision, making it easier to read and watch TV.
Most people with dry AMD keep good vision unless they develop wet AMD. However, some with dry AMD experience rapid and severe loss of central vision due to “wearing out” of the macula, called “geographic atrophy” (GA). Until recently, there has been no treatment for GA. However, RPT can reduce the rate of GA progression by over 50% per year compared to AREDS vitamins. RPT does this safely, while also improving indoor vision and reducing the risk of developing wet AMD. SDM RPT™ is thus the first an only treatment to safely slow progression of AMD, even in the most severe form of dry AMD – geographic atrophy.
If you have “wet” AMD, RPT™ can help in several important ways. As you know, drugs injected into the eye are the primary treatment for wet AMD. RPT™ helps these drugs work better. What does this mean? Real-world data demonstrates that RPT™ decreases the number of injections needed by 80% without sacrificing visual results. By decreasing the number of injections, RPT can reduce the risks of vision-threatening complications of injections, such as macular atrophy, infection and glaucoma.
Studies have shown that the effects of RPT™ in AMD tend to wear off and return to pre-treatment levels about 6-9 months after treatment. Therefore, to maintain maximum treatment benefits to minimize your risks of vision loss from AMD, patients with AMD should consider RPT™ every 3-4 months.
The above claims are the results of large long-term clinical studies published or pending publication in major international peer-reviewed medical journals. They have been verified and confirmed by “Real World Data” analysis comparing demographically matched patients with and without SDM RPT™ from a US national database of over 400,000 AMD patients and 300 retina specialists. (Vestrum Health, for Retinal Protection Sciences, LLC)